Tae Min Kim
Korea National University of Transportation(KR)Gachon University(KR)Albert Einstein College of Medicine(US)Montefiore Medical Center(US)Seoul National University(KR)University of Pittsburgh(US)Yonsei University(KR)Seoul National University Hospital(KR)Seoul National University Bundang Hospital(KR)Korea Institute of Radiological and Medical Sciences(KR)Gyeongsang National University Hospital(KR)National Institute of Allergy and Infectious Diseases(US)Hallym University Sacred Heart Hospital(KR)Ajou University(KR)Jeonbuk National University(KR)Catholic University of Korea(KR)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Lymphoma Diagnosis and Treatment, Cancer Immunotherapy and Biomarkers, Glioma Diagnosis and Treatment, Lung Cancer Research Studies
Most-Cited Works
- → Capmatinib in MET Exon 14–Mutated or MET -Amplified Non–Small-Cell Lung Cancer(2020)977 cited
- → Epacadostat plus pembrolizumab versus placebo plus pembrolizumab in patients with unresectable or metastatic melanoma (ECHO-301/KEYNOTE-252): a phase 3, randomised, double-blind study(2019)915 cited
- → Dabrafenib plus trametinib in patients with previously treated BRAFV600E-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial(2016)871 cited
- → Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma(2019)748 cited
- → Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial(2017)576 cited
- → Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell–Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I/II Trial